Safety and immunogenicity of a polyvalent DNA–protein HIV vaccine with matched Env immunogens delivered as a prime–boost regimen or coadministered in HIV-uninfected adults in the USA (HVTN 124): a phase 1, placebo-controlled, double-blind randomised controlled trial

Ian Frank, Shuying S. Li, Nicole Grunenberg, Edgar T. Overton, Samuel T. Robinson, Hua Zheng, Kelly E. Seaton, Jack Heptinstall, Mary Allen, Kenneth H. Mayer, Daniel A. Culver, Michael C. Keefer, Sri Edupuganti, Michael Pensiero, Vijay Mehra, Stephen C. De Rosa, Daryl E. Morris, Shixia Wang, Michael S. Seaman, David C. Montefiori, Guido Ferrari, Georgia D. Tomaras, James G. Kublin, Lawrence Corey, Shan Lu